Skip to Content
Event ANT Neuromeeting 2026 - Philadelphia starts on Apr 15, 2026, 3:30:00 AM (US/Eastern)
TMS Advances in Clinical Practice
4/16/26, 11:25 AM - 4/16/26, 12:00 PM (US/Eastern) (35 minutes)
TMS Advances in Clinical Practice
Grant Hilary Brenner, MD, DFAPA
Grant Hilary Brenner, MD, DFAPA
Grant Hilary Brenner, MD, DFAPA, is a board-certified psychiatrist, psychoanalyst, and Founder and Director of Brighter NeuroTherapeutics in Manhattan's Flatiron district, specializing in brain-based psychiatry and advanced neuromodulation, including accelerated TMS for treatment-resistant depression. He serves as Principal Investigator for a 2025 open-label study on accelerated TMS and as a consulting investigator on research examining TMS and neuroendocrine function, reflecting a commitment to evidence-based neuromodulation.
A Distinguished Fellow of the American Psychiatric Association and Fellow of the New York Academy of Medicine, Dr. Brenner has received awards for clinical excellence and disaster psychiatry. He teaches psychodynamic psychotherapy at the Manhattan Institute for Psychoanalysis and psychodynamic therapy to medical students at the Icahn School of Medicine at Mount Sinai, with a focus on working with underserved communities.

He is the author of the Irrelationship trilogy, three books exploring psychological patterns in relationships and personal growth, published by Central Recovery Press. His Psychology Today blog, ExperiMentations, has amassed over 14.5 million views and continues to explore the intersection of neuroscience, psychology, ethics, and human transformation.

Dr. Brenner regularly lectures on neuromodulation, artificial intelligence, and psychotherapy, and is committed to advancing a vision of psychiatry rooted in empathy, critical thinking, and compassionate curiosity.
Transcranial magnetic stimulation has moved well beyond its origins as a last-resort intervention for treatment-resistant depression. Today, accelerated TMS protocols, refined targeting strategies, and an expanding evidence base are reshaping how clinicians think about brain-based psychiatric care — and opening new questions about the intersection of neuromodulation, psychotherapy, and patient identity.

This talk draws on Dr. Brenner's clinical and research experience at Brighter NeuroTherapeutics, where accelerated TMS is integrated into a comprehensive, individualized treatment model. He will review key advances in TMS protocols, including accelerated and deep TMS approaches, with attention to what the current evidence supports and where meaningful gaps remain. As Principal Investigator for a 2025 open-label study on accelerated TMS and a consulting investigator on research examining TMS effects on neuroendocrine function, Dr. Brenner brings both frontline clinical perspective and active research engagement to the discussion.

Beyond efficacy data, the talk will address practical considerations for clinical implementation — patient selection, sequencing with pharmacotherapy and psychotherapy, managing expectations, and understanding response variability. Special attention will be given to the emerging framework of TMS-assisted psychotherapy, exploring how neuromodulation may create windows of neuroplasticity that enhance the depth and durability of therapeutic work.

Drawing on his background as a psychiatrist and psychoanalyst, Dr. Brenner will also consider what rapid symptom change means for patients' sense of self, relationships, and psychological continuity — dimensions of care that technology alone cannot address. The integration of neuroscience and humanistic clinical thinking, he argues, is not optional but essential to responsible neuromodulation practice.

Attendees will leave with an updated clinical framework for TMS, practical guidance for patient care, and a broader perspective on where the field is headed.